Home/ Stocks/ ATAI

AtaiBeckley Inc. Common Stock

ATAI XNAS

$7.25 +0.07 (+0.97%) ▲ 15-min delayed

Open

$7.20

High

$7.25

Low

$7.20

Volume

6.41M

Market Cap

$2.66B

About AtaiBeckley Inc. Common Stock

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 99 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$749.0K	$-61,098,000	$-0.28
Q2 2025	$719.0K	$-27,746,000	$-0.14
Q1 2025	$1.55M	$-26,465,000	$-0.15
FY 2024	$308.0K	$-150,049,000	$-0.93

Related Market News

No specific coverage for ATAI yet. Check out our latest market news or earnings calendar.

Get ATAI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on AtaiBeckley Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.